Supernus holders to receive 1.5401 Indivior shares per share; Indivior holders to get a one-time $1 billion special cash dividend pre-close.
Post-close ownership split set at about 56.5% for Indivior shareholders, 43.5% for Supernus shareholders; Rockville, Maryland to serve as global headquarters.
All-stock merger to create CNS-focused drugmaker
Supernus Pharmaceuticals agreed to combine with Indivior Pharmaceuticals in an all-stock transaction, creating a CNS-focused drugmaker with scale.
Combined annual revenue expected at about $2.2 billion; pro forma adjusted EBITDA projected at $888 million.
Deal targets $125 million in annual cost synergies; closing expected in Q4 2026, subject to shareholder and regulatory clearances.
SUPN•
